eurican dhppi2
merial s.a.s., francija - novājinātu destemper viruss, dzīvas novājinātas suņu adenovīrusa (cav2), un dzīvu novājinātu suņu parvovīrusa (cpv), novājinātu parainfluenza 2. tipa vīruss - liofilizāts un šķīdinātājs suspensijas injekcijām pagatavošanai - suņi
suvaxyn parvo-e amphigen
zoetis belgium s.a., beļģija - inaktivēta cūku parvovīrusa, inaktivēta erysipelothrix rhusiopathiae - emulsija injekcijām - cūkas
porcilis ery+parvo+lepto
intervet international bv, nīderlande - cūku parvovīrusa, leptospira canicola, leptospira icterohaemorrhagiae, leptospira grippotyphosa, leptospira pomona, e. rhusiopathiae celma m2, leptospira dienvidiem, leptospira tarassovi - suspensija injekcijām - cūkas
biocan novel puppy
bioveta, a.s., Čehija - suņu distemper virus, celms cdv bio 11/suņu parvovīrusa tips 2, celms, cpv-2b bio-12/b - liofilizāts un šķīdinātājs suspensijas injekcijām pagatavošanai - suņi
biocan dhppi inj. sicc. dzīva liofilizēta vakcīna
bioveta, a.s., Čehija - suņu parvovīrusa - dzīva liofilizēta vakcīna - suņi
porcilis ery + parvo suspensija injekcijām
intervet international b.v., nīderlande - inaktivēta cūku parvovīrusa,inaktivēta erysipelothrix rhusiopathiae - suspensija injekcijām - cūkas
ceprotin
takeda manufacturing austria ag - cilvēka olbaltumviela c. - purpura fulminans; protein c deficiency - antitrombotiskie līdzekļi - ceprotin is indicated for prophylaxis and treatment of purpura fulminans coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein c deficiency.
cryomarex rispens
merial s.a.s., francija - novājinātu marek slimības vīruss, rispens starin - suspensija un šķīdinātājs suspensijas injekcijām pagatavošanai - cāļi
purevax rcp
boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.
purevax rcp felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.